Alberto
Carmona Bayonas
Asociado Ciencias de la Salud
Hospital Virgen del Camino
Pamplona, EspañaPublications en collaboration avec des chercheurs de Hospital Virgen del Camino (23)
2023
-
Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study
PLoS ONE, Vol. 18, Núm. 5 May
-
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Therapeutic Advances in Medical Oncology, Vol. 15
2022
-
Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial
Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661
2021
-
External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
Therapeutic Advances in Medical Oncology, Vol. 13
-
External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?
Gastric Cancer, Vol. 24, Núm. 2, pp. 445-456
-
Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry
Gastric Cancer, Vol. 24, Núm. 4, pp. 926-936
-
Rationale, design and methodology of TESEO study: a registry of thrombosis and neoplasia of SEOM (Spanish Society of Medical Oncology)
Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 799-811
-
Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus
Pancreatology, Vol. 21, Núm. 1, pp. 215-223
2020
-
Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry
Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 734-750
-
Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry
PloS one, Vol. 15, Núm. 7, pp. e0235848
-
TESEO, cancer-associated thrombosis registry from the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology
2019
-
Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
British Journal of Cancer, Vol. 121, Núm. 7, pp. 537-544
-
Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer
Thrombosis and Haemostasis, Vol. 119, Núm. 11, pp. 1849-1859
-
SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018)
Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 75-86
2018
-
Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry
Gastric Cancer, Vol. 21, Núm. 1, pp. 96-105
-
Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis
Journal of Geriatric Oncology, Vol. 9, Núm. 3, pp. 254-264
-
Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry
European Journal of Surgical Oncology, Vol. 44, Núm. 8, pp. 1191-1198
2017
-
Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial
Tumor Biology, Vol. 39, Núm. 6
-
Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: Real-world data from the AGAMENON National Cancer Registry
British Journal of Cancer, Vol. 117, Núm. 6, pp. 775-782
-
Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: A multicenter prospective study in the era of trastuzumab
British Journal of Cancer, Vol. 116, Núm. 12, pp. 1526-1535